Background. Low 25-hydroxyvitamin D (25(OH)D) has been associated with increased HIV mortality, but prospective studies assessing treatment outcomes after combination antiretroviral therapy (cART) initiation in resourcelimited settings are lacking.
25-hydroxyvitamin D concentration is affected by genetics, nutritional status, and factors that affect ultraviolet (UV) light exposure and absorption, such as season, latitude, and skin pigmentation [14] [15] [16] . However, few studies on low 25(OH)D and HIV disease progression have been conducted in multiple geographic settings, and only 1 study, which found an association between 25(OH)D deficiency and mortality, examined this relationship at combination antiretroviral therapy (cART) initiation [9] [10] [11] [12] 17] . Furthermore, no studies examined the association between 25(OH)D level and viral load at baseline and after cART initiation.
The Prospective Evaluation of Antiretrovirals in Resource Limited Settings (PEARLS) trial provided an opportunity to investigate the association between low 25(OH)D and cART outcomes in diverse settings. We used a case-cohort design in the PEARLS trial to assess risk factors for baseline low 25(OH)D in a cohort of human immunodeficiency virus type 1 (HIV-1) infected individuals at cART initiation and prospectively examined its association with HIV disease progression, virologic failure, and immunologic failure post-cART initiation in 8 low-and middle-income countries and the United States. Finding a strong association between low 25(OH)D and HIV treatment outcomes would provide a robust rationale for low 25(OH)D supplementation strategies to reduce HIV-related morbidity and mortality globally.
METHODS

Study Population
Our study population was a nested case-cohort sample of the PEARLS trial (Adult AIDS Clinical Trials Group (ACTG) A5175, ClinicalTrials.gov NCT00084136), an open-label, randomized clinical trial examining once-daily vs twice-daily dosing of 3 cART regimens. The PEARLS study has been described elsewhere [18] . In brief, between May 2005 and July 2007, 1571 HIV-infected adults (18 years or older) with a CD4 + count <300 cells/mm 3 were randomized to 1 of 3 treatment arms: efavirenz plus lamivudine/zidovudine; atazanavir plus didanosine EC, and emtricitabine; or efavirenz plus emtricitabine/tenofovir-DF. Participants were enrolled in Brazil (N = 231), Haiti (N = 100), India (N = 255), Malawi (N = 221), Peru (N = 134), South Africa (N = 210), Thailand (N = 100), United States (N = 210), and Zimbabwe (N = 110). In total, 739 (47%) were women, and 787 (50%) participants were black. Exclusion criteria were pregnancy, acute illness, or acute, serious comorbidities, and specific laboratory abnormalities [18] . A physical exam, CD4 + count, and HIV viral load were scheduled at least every 8 weeks. Diagnostic criteria were standardized across sites using ACTG Appendix 60. Study follow-up ended May 2010. We used a case-cohort design [19] to investigate the association of low 25(OH)D with outcomes after cART initiation. A case was defined as a participant who developed the primary outcome of new WHO Stage 3 or 4 events or death within 96 weeks postcART initiation. Secondary outcomes were virologic failure (defined as 2 successive plasma HIV-1 RNA measurements ≥1000 copies/mL at or after the week 16 visit) and immunologic failure (defined as CD4 + lymphocyte count <100 cells/mm 3 at >48 weeks after cART initiation). Those meeting criteria for secondary outcomes were defined as cases in separate analyses. The full case-cohort was composed of a prespecified, randomly chosen subcohort of 270 participants (30 participants chosen randomly from each country and stratified by randomized treatment arm) and any cases meeting primary or secondary outcomes as defined above and who were not included in the random sub-cohort sample. Cases were compared to those in the random subcohort who did not develop the outcome. The case cohort included a total of N = 411 for primary outcome, n = 378 for virological failure outcome, and n = 278 for immunological failure outcome analyses (Figure 1 ).
Ethics Statement
This study was approved by institutional review boards and ethics committees at Johns Hopkins University and at each participating institution [18] . Written, informed consent was obtained from study participants, and human experimentation guidelines of the US Department of Health and Human Services were followed.
Laboratory Methods
Serum specimens were collected before or at entry to the PEARLS study and were stored at −70°C. Serum vitamin D concentrations were measured at the CLIA-certified Immunology Laboratory at the Johns Hopkins Hospital using the chemiluminescence immunoassay (DiaSorin, Stillwater, MN), which measures both D2 and D3 and is reported as a total serum 25(OH) vitamin D concentration [20] . Plasma HIV-1 RNA concentration was measured in real time by the Roche Amplicor Monitor assay (v1.5, Branchburg, NJ) at site laboratories participating in the DAIDS Virology Quality Assurance program.
Definitions
Low 25(OH)D was defined as 25-OH Vitamin D <32 ng/mL [8] . Severe deficiency was defined as <10 ng/mL, deficiency as 10-20 ng/mL, and insufficiency as >20 to <32 ng/mL. Sufficient vitamin D concentration was defined as ≥32 ng/mL. Currently no clear consensus exists regarding what concentration represents a clinically meaningful marker of insufficiency or deficiency [16, 21] . Thus serum vitamin D was evaluated as a categorical variable, using established clinical cutoffs, and as a continuous variable. Seasons were defined as follows, depending on the hemisphere of the country: spring (months 3-6; southern hemisphere: months 9-11), summer (months 6-8; southern hemisphere: months 12-2), autumn (months 9-11; southern hemisphere: months 3-5), winter (months 12-2; southern hemisphere: months 6-8). Race was defined as black, white, Asian, or other.
To assess weight and height, trained research assistants used standardized procedures. HIV stage was classified per World Health Organization (WHO) guidelines [22] . Patients were asked to recall any history of AIDS-defining illnesses using a standardized questionnaire. Clinical history was performed at scheduled visits at weeks 2, 4, 8, and then every 4 weeks through week 24 and then every 8 weeks. The exact week from randomization was used to calculate event and censoring times. Those not meeting case criteria were censored at the last clinic visit, which could not be >96 weeks.
Statistical Analysis
The random subcohort was used to estimate low 25(OH)D prevalence. Confidence intervals were calculated with Agresti and Coull method. Given the colinearity of race with country, a country-race variable was formulated. Fisher exact test and Wilcoxon tests were used to explore the association of baseline covariates with the outcome of low 25(OH)D. Multivariable logistic regression modeled these associations; the final model included BMI, country-race, season of sample, and viral load.
The full case-cohort sample was used to assess clinical outcomes associated with baseline low 25(OH)D. Cox proportional hazards regression was performed with partial likelihood weighting adjustment to account for the case-cohort sampling [19, 23] . The time to first qualifying event ( primary outcome or 1 of 2 secondary outcomes) was calculated from cART initiation. All models were stratified by country and randomized treatment arm. The final multivariable models included season, BMI, race, CD4 count, and viral load. A history of AIDS-defining illness was a prespecified risk factor for poor clinical outcomes based on previous studies, but low 25(OH)D was hypothesized to be causally associated with both a history of AIDS-defining illness and poor outcomes. An additional multivariable model that also included history of AIDS-defining illness was included. An analysis using 25(OH)D concentration as a continuous variable was performed to assess a dose-related relationship between 25(OH)D and primary and secondary outcomes. Finally, possible nonlinear relationships between 25(OH)D and primary and secondary outcomes were explored nonparametrically using cubic splines.
RESULTS
Study Population and Comparison of Included and Excluded Persons
The random subcohort was comparable to the larger PEARLS parent study sample, except for country, which was the basis for the random subcohort stratification (data not shown). 20 of the 270 participants assigned to the random subcohort were excluded from analyses for missing baseline vitamin D data, as were an additional 9 subjects who met a case definition for the primary or secondary outcomes. Most missing vitamin D data were from India due to difficulties in exporting samples. Apart from country and race, participants with missing data were significantly more likely to be underweight; they were otherwise similar to the full case-cohort sample (data not shown). In the PEARLS trial, 192 (12%) of 1571 participants had incident WHO stage 3 or 4 or death by 96 weeks (Figure 2 ). Of these cases, 31 were already included in the random subcohort. The remaining 161 cases (Supplementary Table 1 ) were added to these and the 219 controls without the primary outcome to create the full casecohort for the primary outcome (n = 411).
Baseline 25-OH Vitamin D Concentration and Associated Factors
The random subcohort (n = 250) was used to estimate prevalence of low 25(OH)D and to identify baseline characteristics associated with baseline low 25(OH)D (Table 1) . Overall prevalence of low 25(OH)D was 122/250 (49%; 95% CI, 43-55); 4 (2%) subjects (all from the US) had severe deficiency, 34 (14%) had deficiency, and 84 (34%) had insufficiency.
Prevalence of low 25(OH)D varied significantly by country, race and season; it ranged from 7/30 (27%) in Brazil to 21/27 (78%) in Thailand and 13/18 (72%) in India ( Additionally, those assessed in winter (n = 57/99; aOR 3.75, 95% CI, 1.53-9.73) or spring (n = 32/57; aOR 2.58, 95% CI, 1.04-6.67) compared to summer (n = 26/68), and those with lower baseline viral load had higher odds of low 25(OH)D (aOR 1.46 per log 10 decrease, 95% CI, .97-2.24; Supplementary Figure 1 ). An analysis of vitamin D concentration by category (severe deficiency, deficiency, insufficiency, and sufficient) identified the same significant risk factors (data not shown).
Progression to Clinical Events
In the full case-cohort for the primary outcome (n = 411), of 192 cases who experienced a new WHO stage 3 or 4 disease or death Figure 3A ).
Among the case-cohort for the secondary outcome of virologic failure (n = 378), 152 participants experienced virologic failure. Table 3 ). This relationship remained statistically significant in all multivariate models and in analysis of 25(OH)D concentration as a continuous variable ( Figure 3B ). Finally, there were few immunologic failure events (n = 29). Although baseline low 25(OH)D was associated with immunological failure in univariate analysis (HR 3.78, CI, 1.19-12.0), this relationship was attenuated in multivariate models (Table 3) .
DISCUSSION
Although several studies have examined risk factors for low 25-hydroxyvitaimin D in HIV-infected adults, we are unique in assessing this in a diverse, treatment-naive population, primarily from middle-and low-income countries where HIV burden is most prevalent. We found substantial differences in prevalence of 25(OH)D by country, race, season, and BMI. Most importantly, we found an association between baseline low 25(OH)D and risk of HIV disease progression, death, and notably virologic failure post-cART initiation. To our knowledge, this is the first time low 25(OH)D has been associated with HIV virologic failure and represents a novel risk factor for virologic failure.
Prevalence Estimates and Risk Factors Compared to Other Studies
We found that 49% of study participants in the random subcohort had low 25(OH)D, a prevalence similar to that reported in the US SUN cohort and other cohorts [24] [25] [26] [27] . However, few studies have assessed pre-cART 25(OH)D levels, an important distinction, as cART itself can affect serum 25(OH)D levels [28] [29] [30] . In addition, we chose a higher prespecified cutoff of <32 ng/mL because, although severe vitamin D deficiency was relatively uncommon in our study, vitamin D insufficiency was relatively common in all country-race groups and has widespread clinical relevance [8] . More importantly, this is the most varied group of HIV-infected patients to have low 25(OH)D risk factors assessed. Genetics, nutrition, seasonal patterns, skin pigmentation, and sun exposure, including sun-avoidant cultural practices, affect serum 25(OH)D levels, contributing to the wide range in prevalence of low 25(OH)D across countries and racial groups studied. Our study confirms the We also observed a significant association between low 25(OH)D and BMI, an important relationship in resourcelimited populations with suboptimal nutrition. Interestingly, our study had higher proportions of overweight and obese individuals than undernourished individuals, a finding largely driven by the United States, South Africa, and Brazil. Being overweight or obese may be associated with less active lifestyle and therefore less sun exposure. Perhaps more relevant is that 25(OH)D appears to be sequestered in adipose tissue, a hormonally active tissue that plays a role in inflammation and throughout which vitamin D receptors are found. Vitamin D metabolites also influence the inflammatory response in adipose tissue in multiple ways, including modulating the release of proinflammatory factors such as MCP-1 and IL-6 by human preadipocytes [31, 32] .
Low 25-hydroxyvitamin D Associated with HIV Disease Progression and Virological Failure
Our finding that low 25(OH)D was independently associated with higher rates of clinical progression and death is biologically plausible given the wealth of studies now emerging on the diverse roles of vitamin D in the immune system. Vitamin D regulates inflammatory cytokines [33] , modulates adaptive immune responses, and controls T-cell activation [4] , and Bcell proliferation [34] . 25(OH)D upregulation is associated with the peptide cathelicidin, important in killing intracellular pathogens such as Mycobacteiun tuberculosis which accounted for 30% of primary outcome events in this study. Studies demonstrate that polymorphisms of the vitamin D receptor are associated with faster progression to AIDS in HIV-infected patients [35, 36] and increased susceptibility to diseases such as tuberculosis in certain populations [37, 38] . Our findings are also consistent with the few studies investigating the association between 25(OH)D concentration and HIV outcomes, including the EuroSIDA cohort study and studies conducted in Tanzania. Only one of these enrolled patients initiating cART and did not assess the association between viral load and 25(OH)D levels [9] [10] [11] [12] 17] .
Our examination of the relationship between 25(OH)D and viral load indicates a mechanism that may explain the association between disease progression and low 25(OH)D. We were able to prospectively examine viral load in the PEARLS study due to frequent monitoring, close follow-up, and quality assurance guaranteeing consistency across sites. We found, paradoxically, that 25(OH)D at baseline has a non-statistically significant association with lower viral load; higher 25(OH)D levels in the face of elevated viral loads prior to cART initiation may result from increased systemic immune activation and modulation of vitamin D by activated macrophages, but this finding needs further investigation.
The novel finding that low 25(OH)D was associated with virologic failure after cART initiation is easier to explain. Studies indicate that 25(OH)D plays a role in inhibiting viral replication in multiple viruses, including respiratory viruses such as influenza and RSV, herpes simplex virus, and adenoviruses [39, 40] . Low 25(OH)D levels have recently been associated with high levels of hepatitis B viral replication [6] . Furthermore, similar to our results with HIV patients initiating cART, for HIV/HCV coinfected patients, lower 25(OH)D levels resulted in impaired virologic responses to anti-HCV treatment [41] . 25(OH)D defends against these viruses through the induction of antiviral genes including cathelicidin and β-defensin 4 and the release of reactive oxygen species [39] . 25(OH)D reduces inflammatory cytokine production, decreases T-cell activation, and shifts the T-cell profile from a Th1 response to Th2 response [42] . As HIV infections are Our study has limitations. The study participants were enrolled in a clinical trial and were excluded if they had any major comorbidities or laboratory abnormalities. Therefore, they were relatively healthy compared to many patients initially evaluated in routine HIV care programs. Also, as immunologic failure events were infrequent, the study lacked power to detect a statistically significant increase in immunologic failure as a result of low 25(OH)D. We also did not collect data on possible 25(OH)D supplementation, but this was not common at the time this study was conducted and unlikely to have occurred in resource-limited settings. The associations found in this article raise questions of reverse causation: does advanced HIV disease cause low 25(OHD) concentrations; or, is low 25(OH)D concentration a general marker for poor health? The fact that the study was prospective and that severely ill persons were excluded from the study make this less likely. Also, 25(OH)D concentrations were comparable to those found in studies of non-HIV infected persons in similar populations [45] [46] [47] .
CONCLUSION
Our study demonstrated high prevalence of low 25(OH)D among HIV-infected persons in a wide variety of settings. We showed prospectively that low 25(OH)D is a predictor of poor clinical outcomes among HIV-infected adults in diverse geographic, economic, and cultural settings. Furthermore, the novel association of low 25(OH)D with virologic failure is biologically plausible, but it remains unknown whether 25-hydroxyvitamin D supplementation could improve cART outcomes, particularly in resource-limited settings where the burden of disease lies. Our findings support the concept that 25-hydroxyvitamin D supplementation may be an inexpensive, safe therapeutic addition for HIV-infected persons, but clearly a well-designed clinical trial is needed.
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